The NCI's Clinical Proteomic Technologies for Cancer (CPTC) initiative has made tremendous progress knocking down barriers to the field which is indicative of both the dedication to the highest quality of research by its investigators and commitment to open standards.
CPTC experts authored a review of the current state of clinical proteomics
CPTC held its fourth annual meeting in Bethesda, MD, on September 8-9, 2010, bringing together a record number of attendees-more than 300 participants-representing the full breadth of scientific fields that contribute to the initiative's mission.
The AACC has a number of key goals as it moves into 2011 including: developing ways to continue working with industry within the new AdvaMed guidelines; developing ways in which the AACC can collaborate more with other professional medical associations; increasing the recognition of translational science at our annual meeting; and continuing our global outreach
Approximately 60 percent of patients diagnosed with cancer present as early stage disease (Stage I and II). Despite the favorable prognosis associated with treatment intervention of such early stage disease (typically surgical excision), there are a small, but significant, fraction of these cancers that appear to be hardwired for aggressive metastatic behavior and ultimately lethal outcome.
"Cancer is a disease of the genome," noted Lynda Chin, M.D., professor of dermatology, Harvard Medical School and Dana-Farber Cancer Institute. "And understanding the impact of genomic changes in the proteome is critically important for converting genomic knowledge into something that a clinician can use on their patients."
Additional antibodies are now available on the CPTC Reagent & Data Portal.